Clinical Data ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD Pharmaceutical TechnologyPABPC4 genetic variants found to be associated with mitochondrial dysfunction driving emphysema in COPD.RespiratoryRead full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology PABPC4 genetic variants found to be associated with mitochondrial dysfunction driving emphysema in COPD. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosisNext: Bayer gets swift review for Kerendia in type 1 diabetes Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
